Biohit Oyj B - Asset Resilience Ratio
Biohit Oyj B (BIOBV) has an Asset Resilience Ratio of 24.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Biohit Oyj B's Asset Resilience Ratio has changed over time. Check Biohit Oyj B PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Biohit Oyj B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Biohit Oyj B.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.50 Million | 17.68% |
| Short-term Investments | €1.30 Million | 6.57% |
| Total Liquid Assets | €4.80 Million | 24.24% |
Asset Resilience Insights
- Good Liquidity Position: Biohit Oyj B maintains a healthy 24.24% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biohit Oyj B Industry Peers by Asset Resilience Ratio
Compare Biohit Oyj B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Beijing Succeeder Technology Inc
SHG:688338 |
Medical Devices | 28.27% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 34.47% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.30% |
Annual Asset Resilience Ratio for Biohit Oyj B (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Biohit Oyj B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.24% | €4.80 Million ≈ $5.61 Million |
€19.80 Million ≈ $23.15 Million |
-19.04pp |
| 2024-12-31 | 43.28% | €6.71 Million ≈ $7.84 Million |
€15.50 Million ≈ $18.12 Million |
-9.46pp |
| 2023-12-31 | 52.74% | €6.81 Million ≈ $7.97 Million |
€12.92 Million ≈ $15.10 Million |
-3.79pp |
| 2022-12-31 | 56.53% | €6.23 Million ≈ $7.28 Million |
€11.02 Million ≈ $12.88 Million |
-0.84pp |
| 2021-12-31 | 57.37% | €5.51 Million ≈ $6.45 Million |
€9.61 Million ≈ $11.24 Million |
+0.96pp |
| 2020-12-31 | 56.41% | €6.08 Million ≈ $7.11 Million |
€10.78 Million ≈ $12.60 Million |
+10.38pp |
| 2019-12-31 | 46.03% | €8.00 Million ≈ $9.35 Million |
€17.37 Million ≈ $20.31 Million |
+1.29pp |
| 2018-12-31 | 44.74% | €8.00 Million ≈ $9.36 Million |
€17.89 Million ≈ $20.91 Million |
+5.71pp |
| 2017-12-31 | 39.03% | €7.38 Million ≈ $8.62 Million |
€18.89 Million ≈ $22.09 Million |
-15.89pp |
| 2016-12-31 | 54.92% | €7.13 Million ≈ $8.34 Million |
€12.99 Million ≈ $15.19 Million |
-0.65pp |
| 2015-12-31 | 55.58% | €6.52 Million ≈ $7.62 Million |
€11.73 Million ≈ $13.71 Million |
-12.04pp |
| 2014-12-31 | 67.62% | €9.81 Million ≈ $11.47 Million |
€14.51 Million ≈ $16.96 Million |
+13.77pp |
| 2013-12-31 | 53.84% | €15.24 Million ≈ $17.82 Million |
€28.30 Million ≈ $33.09 Million |
-21.73pp |
| 2012-12-31 | 75.57% | €30.23 Million ≈ $35.35 Million |
€40.01 Million ≈ $46.77 Million |
+61.58pp |
| 2011-12-31 | 13.99% | €10.00 Million ≈ $11.69 Million |
€71.47 Million ≈ $83.56 Million |
+12.29pp |
| 2010-12-31 | 1.70% | €500.00K ≈ $584.55K |
€29.38 Million ≈ $34.35 Million |
+0.24pp |
| 2009-12-31 | 1.46% | €400.00K ≈ $467.64K |
€27.40 Million ≈ $32.03 Million |
-0.31pp |
| 2008-12-31 | 1.77% | €480.00K ≈ $561.17K |
€27.11 Million ≈ $31.69 Million |
-1.61pp |
| 2007-12-31 | 3.38% | €923.00K ≈ $1.08 Million |
€27.34 Million ≈ $31.96 Million |
+0.24pp |
| 2006-12-31 | 3.13% | €856.00K ≈ $1.00 Million |
€27.32 Million ≈ $31.94 Million |
-5.48pp |
| 2005-12-31 | 8.62% | €2.40 Million ≈ $2.81 Million |
€27.85 Million ≈ $32.56 Million |
+8.63pp |
| 2004-12-31 | -0.02% | €-4.00K ≈ $-4.68K |
€22.76 Million ≈ $26.61 Million |
-- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more